

姓名	王润玲	职称	教授	所在部门	药学院	研究方向	基于靶点的创新药物研究	
办公室	药学院A楼302	电话	13602030967	电子邮箱	wangrunling@tmu.edu.cn			
教育背景								
<p>1978年8月—1982年7月北京大学医学部，本科学历，学士学位。</p> <p>2003年8月—2006年7月天津大学，研究生学历，博士学位。</p> <p>2001年8月-2002年7月 瑞典乌普萨拉大学，有机化学系，高级访问学者。</p>								
工作经历								
<p>2015.5-至今 天津医科大学药学院，教授</p> <p>1999.10-2015.4 天津医科大学药学院，教授，副院长</p> <p>1994.10-1999.9 天津医科大学药学院，副教授</p> <p>1984.10-1994.9 天津医科大学药学院，讲师</p> <p>1982.7-1984.9 天津医科大学药学院，助教</p>								
研究成果（本人具有代表性的论著、论文及主持的科研项目）								
论著及编著	<p>药物化学（主编）清华大学出版社，第二版，2018.5</p> <p>药物化学（主编）清华大学出版社，第一版，2013.7</p> <p>药物化学（主编）医药科技出版社，第三版，2012.5，</p> <p>药学专业化学实验II（主编），人民卫生出版社，2008.7</p> <p>药物化学（参编），人民卫生出版社，第八版，2016.2</p> <p>药物化学（参编），人民卫生出版社，第七版，2011.8 7</p> <p>药物化学（参编），中国医药科技出版社，第二版，2011.2</p> <p>临床药物化学（参编），人民卫生出版社，2007.8</p> <p>现代药物设计学（参编），中国医药科技出版社，2006</p>							
论文	<p>1. Ma Yangchun, Yang WenYu, Zhou Liang, Li LiPeng, Wu JingWei, Li WeiYa, Du Shan, Ma Ying* & Wang RunLing*. Exploring the cause of the dual allosteric targeted inhibition attaching to allosteric sites enhancing SHP2 inhibition. [J]. <i>Molecular Diversity</i>, 2021. Doi: 10.1007/s11030-021-10286-4.</p> <p>2. Hao-Xin Li, Wen-Yu Yang, Li-Peng Li, Hui Zhou, Wei-Ya Li, Ying Ma*,</p>							

- Run-Ling Wang***. Molecular dynamics study of CDC25B^{R492L} mutant causing the activity decrease of CDC25B. [J]. *Journal of Molecular Graphics and Modelling*. 2021; 109: 108030.
3. Shan Du, Xin-hua Lu, Wei-Ya Li, Li-Peng Li, Yang-Chun Ma, Liang Zhou, Jing-Wei Wu, Ying Ma* & **Run-Ling Wang***. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2^{E69K}. [J]. *Molecular Diversity*. 2021; 25, 1873–1887.
 4. Ying-Zhan Sun, Jing-Wei Wu, Shan Du, Yang-Chun Ma, Liang Zhou, Ying Ma*, **Run-Ling Wang***. Design, synthesis, biological evaluation and molecular dynamics of LAR inhibitors. [J]. *Computational Biology and Chemistry*. 2021; 92, 107481.
 5. Liang Zhou, Yong Feng, Yang-Chun Ma, Zhao Zhang, Jing-Wei Wu, Shan Du, Wei-Ya Li, Xin-Hua Lu, Ying Ma*, **Run-Ling Wang***. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2^{WT} and SHP2^{F285S} by molecular dynamics study. [J]. *Journal of Molecular Graphics and Modelling*. 2021; 103, 107807.
 6. Wen-Shan Liu, Bing Yang, Rui-Rui Wang, Wei-Ya Li, Yang-Chun Ma, Liang Zhou, Shan Du, Ying Ma*, **Run-Ling Wang***. Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors. [J]. *Bioorganic Chemistry*. 2020; 100, 103875.
 7. Wei-Ya Li, Ying Ma*, Hao-Xin Li, Xin-Hua Lu, Shan Du, Yang-Chun Ma, Liang Zhou, **Run-Ling Wang***. Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation. [J]. *Bioorganic Chemistry*. 2020; 105, 104391.
 8. Jingwei Wu, Weiya Li, Zihui Zheng, Xinhua Lu, Huan Zhang, Ying Ma* and **Runling Wang***. Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxyethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors. [J]. *Journal of biomolecular structure & dynamics*. 2020; 39(4): 1174-1188.
 9. Jing-Wei Wu, Huan Zhang, Wei-Ya Lia, Xue Tang, Hong-Lian Li, Xin-Hua Lu, Zhi-Hui Zheng, Ying Ma* and **Run-Ling Wang***. Design potential selective inhibitors for human leukocyte common antigen-related (PTP-LAR) with fragment replace approach. [J]. *Journal of biomolecular structure & dynamics*. 2020; 38(18): 5338-5348.
 10. Liang Zhou, Yong Feng, Yang-Chun Ma, Zhao Zhang, Jing-Wei Wu, Shan Du, Wei-Ya Li, Xin-Hua Lu, Ying Ma*, **Run-Ling Wang***. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2^{WT} and SHP2^{F285S} by molecular dynamics study, [J]. *Journal of molecular graphics & modelling*. 2020; 103 107807.
 11. Jingwei Wu, Yangchun Ma, Hui Zhou, Liang Zhou, Shan Du, Yingzhan Sun, Weiya Li, Weili Dong*, **Runling Wang***. Identification of protein tyrosine phosphatase 1B (PTP1B) inhibitors through De Novo Evoluton,

- synthesis, biological evaluation and molecular dynamics simulation. [J]. *Biochemical and biophysical research communications*. 2020; 526(1): 273-280.
12. Jingwei Wu, Huan Zhang, Guilong Zhao*, and **Runling Wang***. Allosteric inhibitors of SHP2: an updated patent review (2015-2020). [J]. *Current Medicinal Chemistry*. 2020; 27:1-17
 13. Wen-Shan Liu, Wen-Yan Jin, Liang Zhou, Xing-Hua Lu, Wei-Ya Li, Ying Ma* & **Run-Ling Wang***. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation. [J]. *Journal of Computer-Aided Molecular Design*. 2019; 33(8):759-774.
 14. Wen-Shan Liu, Rui-Rui Wang, Ying-Zhan Sun, Wei-Ya Li, Hong-Lian Li, Chi-Lu Liu, Ying Ma*, **Run-Ling Wang***. Exploring the effect of inhibitor AKB-9778 on VE-PTP by molecular docking and molecular dynamics simulation. [J]. *Journal of Cellular Biochemistry*. 2019; 120(10): 17015-17029.
 15. Li Wei-Ya, Duan Yu-Qing, Ma Yang-Chun, Lu Xin-Hua, Ma Ying*, **Run-Ling Wang***. Exploring the cause of the inhibitor 4AX attaching to binding site disrupting protein tyrosine phosphatase 4A1 trimerization by molecular dynamic simulation. [J]. *Journal of Biomolecular Structure & Dynamics*. 2019; 37(18): 4840-4851.
 16. Yang-Chun Ma, Bing Yang, Xin Wang, Liang Zhou, Wei-Ya Li, Wen-Shan Liu, Xin-Hua Lu, Zhi-Hui Zheng, Ying Ma*, **Run-Ling Wang***. Identification of novel inhibitor of protein tyrosine phosphatases delta: structure-based pharmacophore modeling, virtual screening, flexible docking, molecular dynamics simulation, and post-molecular dynamics analysis. [J]. *J Biomol Struct Dyn*. 2019; 38(15): 4432-4448.
 17. Shan Du, Bing Yang, Xin Wang, Wei-Ya Li, Xin-Hua Lu, Zhi-Hui Zheng, Ying Ma*, **Run-Ling Wang***. Identification of potential leukocyte antigen-related protein (PTP-LAR) inhibitors through 3D QSAR pharmacophore-based virtual screening and molecular dynamics simulation. [J]. *J Biomol Struct Dyn*. 2019; 38(14): 4232-4245.
 18. Wen-Shan Liu, Rui-Rui Wang, Hai Yue, Zhi-Hui Zheng, Xin-Hua Lu, Shu-Qing Wang, Wei-Li Dong*, **Run-Ling Wang***. Design, synthesis, biological evaluation and molecular dynamics studies of 4-thiazolinone derivatives as Protein tyrosine phosphatase 1B (PTP1B) inhibitors. [J]. *J Biomol Struct Dyn*. 2019; 38(13): 3814-3824.
 19. Wen-Shan Liu, Rui-Rui Wang, Wei-Ya Li, Mei Rong, Chi-Lu Liu, Ying Ma*, **Run-Ling Wang***. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation. [J]. *J Biomol Struct Dyn*. 2019; 38(9): 2509-2520.
 20. Rui-Rui Wang, Wen-Shan Liu, Liang Zhou, Ying Ma*, **Run-Ling Wang***. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain containing protein tyrosine phosphatase (SHP2) inhibitor at

	<p>molecular Level through molecular docking and molecular dynamics. [J]. <i>J Biomol Struct Dyn</i>. 2019; 38(5): 1525-1538.</p> <p>21. Rui-Rui Wang, Ying Ma, Shan Du, Wei-Ya Li, Ying-Zhan Sun, Hui Zhou, Run-Ling Wang*. Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics. [J]. <i>Computational Biology and Chemistry</i>. 2019; 78: 133-143.</p> <p>22. Ying-Zhan Sun, Jing-Wei Wu, Xin-Hua Lu, Ying Ma*, Run-Ling Wang*. Exploring the effect of aplidin on low molecular weight protein tyrosine phosphatase by molecular docking and molecular dynamic simulation study. [J]. <i>Computational Biology and Chemistry</i>. 2019; 83: 107123.</p> <p>23. Jing-Wei Wu, Ling Yin, Yu-Qiang Liu, Huan Zhang, Ya-Fei Xie, Run-Ling Wang*, Gui-Long Zhao*. Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout. [J]. <i>Bioorganic & Medicinal Chemistry Letters</i>, 2019; 29(3): 383-388.</p> <p>24. Jingwei Wu, Yingzhan Sun, Hui Zhou, Ying Ma*, Runling Wang*. Design, synthesis, biological evaluation and molecular dynamics simulation studies of (R)-5-methylthiazolidin-4-One derivatives as megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) inhibitors for the treatment of type 2 diabetes. [J]. <i>Journal of Biomolecular Structure & Dynamics</i>. 2019; 38(11): 3156-3165.</p> <p>25. Liang Zhou, Yang-Chun Ma, Xue Tang, Wei-Ya Li, Ying Ma* & Run-Ling Wang*, Identification of the potential dual inhibitor of protein tyrosine phosphatase sigma and leukocyte common antigen-related phosphatase by virtual screen, molecular dynamic simulations and postanalysis. [J]. <i>Journal of Biomolecular Structure & Dynamics</i>. 2019; 39(1): 45-62.</p> <p>26. Chen Li, Tan Xiao-li, ANTAL Rockenbauer, Wang Run-ling*, Liu Yang-ping*. Efficient Synthesis and Characterization of PEGylated/Deuterated Derivatives of Monophosphonated Tetrathiatriarylmethyl Radicals, [J]. <i>Chinese Journal of Magnetic Resonance</i>. 2019; 36(2): 208-218.</p>
科研 项目	<p>1.国家自然科学基金面上项目（81773569）：与幼年型粒单细胞性白血病相关的 SHP2 突变体 E76K、D61G 选择性抑制剂的设计、合成及其活性研究，2018.01-2021.12；</p> <p>2.国家自然科学基金国际（地区）合作与交流项目（81611130090）：以 SHP2 为靶点的抗白血病药物的设计、合成及活性筛选，2016.1.1-2018.12.31；</p> <p>3.国家自然科学基金面上项目（81273361）：高选择性蛋白酪氨酸磷酸酶 SHP2 抑制剂的研究、2013.01-2016.12；</p> <p>4.国家自然科学基金面上项目（20972112）：具有 PTP-1B、PPAR-α、PPAR-γ 三重作用的抗糖尿病先导物的设计、合成及活性研究、2010.01-2012.12；</p> <p>5.天津市自然科学基金重点项目：09JCZDJC21600、基于 PTP1B 酶结构的新型降糖药先</p>

导物的研究、2009.4-2012.3;

6.高等学校博士学科点专项科研基金(20091202110010):具有三靶标(PTP-1B、PPAR- α/γ)作用的抗糖尿病先导物的设计、合成及活性研究,2010.01-2012.12。

7.选择性 SHP2 突变体 D61G、E76K 抑制剂研究,天津市自然科学基金重点项目,(16JCZDJC32500),2016.4-2019.3

荣誉奖励

2016 年获得第九届天津市高等学校教学名师奖;

2009 年被评为天津市优秀教师;

2009 年主持完成的《药学专业实践教学的改革与实践》获高等教育天津市级教学成果二等奖;

2008 年获天津医科大学教学成果一等奖;

2013 年获得“第十二届‘挑战杯’天津市大学生课外学术科技作品竞赛优秀指导教师奖;

2003 年主持研发的《精氨酸布洛芬及其糖浆剂》获天津市科技进步三等奖;

1997 年主持的《布洛芬糖浆剂生物利用度研究》项目获天津市卫生局科技进步三等奖;

2003 年度获天津市“十五”立功先进个人荣誉称号;

2001 年主持的化学实验 II 改革获天津市教委实验室建设单项奖。

2006 年获天津医科大学“十五”科技工作先进个人;

2012 年获得“天津医科大学科技创新优秀指导教师”荣誉称号;

2002 年“九五”期间在科学研究过程中,获得天津医科大学突出贡献奖;

2001 年、1999 年被评为天津医科大学优秀教师;

1997 年获天津市卫生局优秀青年技术人员称号;

1998-2000 年获天津医科大学跨世纪人才资助;